Table 1 Summary of all cases submitted to E1412. Ineligibility rate was high for reasons of tissue inadequacy as well as ineligible diagnosis on ECPR. Seventy-three study slots were preserved because of real-time ECPR

From: Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era

 

Total submitted cases

Rejected before study enrollment “Step 0”

Total enrolled in E1412 after CPR

Total Rejected by CPR (%)

Inadequate tissue (%)

Total Ineligible diagnosis (%)

Ineligible by submitted diagnosis (%)

Ineligible by reviewed diagnosis (%)

Total pathology eligible for analysis (%)

Pre-amendment

208

0

208

74 (35.6)

27 (13.0)

47 (22.6)

7 (3.4)

40 (19.2)

134 (64.4)

Post-amendment

219

73

146

73 (33.3)

26 (11.9)

47 (21.5)

15 (6.8)

32 (14.6)

146 (66.7)

Total

427

73

354

147 (34.4)

53 (12.4)

94 (22.0)

22 (5.2)

72 (16.9)

280 (65.6)